| Foad I Abandeh, MBBS | |
|
1001 Briggs Rd Ste 250, Mount Laurel, NJ 08054-4111 | |
| (856) 866-7466 | |
| (856) 866-9088 |
| Full Name | Foad I Abandeh |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 19 Years |
| Location | 1001 Briggs Rd Ste 250, Mount Laurel, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013215854 | NPI | - | NPPES |
| 1013215854 | Medicaid | VA | |
| 103315220-0001 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | MD461213 (Pennsylvania) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | 25MA11097500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Virtua Willingboro Hospital | Willingboro, NJ | Hospital |
| Virtua Memorial Hospital Of Burlington County | Mount holly, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea's unique and proprietary antigen discovery technology. The combination of Genocea's novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.
Rethink Autism, an educational technology company that produces online research-based treatment tools for parents and professionals, offers some suggestions and a free online set of video tips to help families address some of these challenges and enjoy the holidays.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
Researchers in Israel have conducted a study showing that the immunity provided against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease (COVID-19) – is similar following natural infection or immunization with the Pfizer-BioNTech BNT162b2 vaccine.
Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.
› Verified 3 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea's unique and proprietary antigen discovery technology. The combination of Genocea's novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.
Rethink Autism, an educational technology company that produces online research-based treatment tools for parents and professionals, offers some suggestions and a free online set of video tips to help families address some of these challenges and enjoy the holidays.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
Researchers in Israel have conducted a study showing that the immunity provided against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease (COVID-19) – is similar following natural infection or immunization with the Pfizer-BioNTech BNT162b2 vaccine.
Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Foad I Abandeh, MBBS 301 Lippincott Dr Ste 410, Marlton, NJ 08053-4197 Ph: (856) 355-0340 | Foad I Abandeh, MBBS 1001 Briggs Rd Ste 250, Mount Laurel, NJ 08054-4111 Ph: (856) 866-7466 |
News Archive
Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea's unique and proprietary antigen discovery technology. The combination of Genocea's novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.
Rethink Autism, an educational technology company that produces online research-based treatment tools for parents and professionals, offers some suggestions and a free online set of video tips to help families address some of these challenges and enjoy the holidays.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the peer-reviewed journal Molecular Therapy has published a paper entitled "Comparative Analysis of Immune Responses Induced by Vaccination With SIV Antigens by Recombinant Ad5 Vector or Plasmid DNA in Rhesus Macaques." The paper, co-authored by researchers from Merck, University of Pennsylvania School of Medicine, and Inovio Pharmaceuticals, notes that significant advances in the design, formulation, and delivery of DNA plasmid-based vaccines have dramatically increased their ability to induce antigen-specific immune responses.
Researchers in Israel have conducted a study showing that the immunity provided against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease (COVID-19) – is similar following natural infection or immunization with the Pfizer-BioNTech BNT162b2 vaccine.
Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.
› Verified 3 days ago
Dr. Sherin Mary Thomas Meledathu, D.O. Infectious Disease Medicare: Medicare Enrolled Practice Location: 1001 Briggs Rd Ste 250, Mount Laurel, NJ 08054 Phone: 856-866-7466 Fax: 856-866-9088 | |
Yize Richard Wang, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 501 Fellowship Rd, Suite 101, Mount Laurel, NJ 08054 Phone: 856-642-2133 Fax: 856-642-2134 | |
Dr. Joshua Peter Desipio, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 501 Fellowship Rd, Suite 101, Mount Laurel, NJ 08054 Phone: 856-963-3572 Fax: 856-338-9211 | |
Dr. Jeffrey M Sumerson, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1001 Briggs Rd, Suite 250, Mount Laurel, NJ 08054 Phone: 856-866-7466 Fax: 856-866-9088 | |
Dr. Thanuja K Hamilton, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 204 Ark Road, Suite 206 Lmc I, Mount Laurel, NJ 08054 Phone: 856-778-4640 Fax: 856-778-8862 | |
Dr. Richard F Golden, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1001 Briggs Rd, Suite 250, Mount Laurel, NJ 08054 Phone: 856-866-7466 Fax: 856-866-9088 |